Annual financial report
for the year ended
30 June 2019
MedAdvisor Limited
ABN 17 145 327 617
MedAdvisor’s (ASX: MDR) core purpose is to tackle the global issue of medication
non-adherence and poor health literacy to drive improved health outcomes for
patients by making medication manageable.
Contents
Chairman’s letter
FY19 Results summary & highlights
Directory
Directors’ reports
Auditor’s independence declaration
Corporate governance statement
Financial report for year ended 30 June 2019
Directors’ declaration
Independent auditor’s report
Shareholder information
1
3
8
9
23
24
25
63
64
68
Chairman’s Letter
Dear Shareholders,
I would like to thank you for your support and bid a
warm welcome to shareholders who have joined us
this year.
We are delighted to share our strong domestic
performance, with total revenues increasing by 24% to
$9.2m (vs $7.4m in FY18), and operating revenue
increasing by 25% to $8.2m vs $6.6m in FY18.
MedAdvisor has consolidated its leadership position in
the Australian community pharmacy network, with
over 55% of pharmacies licensing PlusOne to connect
to and support their patients. Over 1.2m Australians
are now digitally connected through MedAdvisor,
helping them to make medication manageable. We
ran 58 funded Health Programs in FY19, generating
$1m in revenue (+48% from FY18) for 23 different
health program funders.
Building from this strong core, the team have made
great progress
in globalising the platform and
identifying partners and customers eager to deploy
MedAdvisor into new markets. As we enter FY20, the
pathway to revenues from at least three new markets
is clear.
US
In FY19, we built a strong, experienced team to
conclude the partnerships and build the relationships
needed for long term success in the market. A
commercial partnership was struck with Adheris
Health, the leading provider of patient adherence and
to US pharmaceutical
engagement
initial 12 month partnership
companies. The
agreement opens up MedAdvisor’s Health Programs
for the benefit of the ~197m US customers of 26,000+
pharmacies that Adheris Health already works with.
We expect revenues from the US to begin to flow from
late 1HFY20.
solutions
Asia
In May 2019, we completed the formation of a 50:50
joint venture with Zuellig Pharma Holdings Pte Ltd
(“Zuellig Pharma”). Zuellig Pharma’s $US13 billion
business provides healthcare services to over 350,000
medical
clinics,
hospitals) across South East Asia, and works with over
1,000 corporate clients,
top 20
pharmaceutical companies in the world.
(pharmacies, medical
including
facilities
the
The 50:50 joint venture subsequently signed its first
pharmacy chain customer, MedExpress Drugstores
(“MedExpress”). MedExpress is the leading hospital
outpatient pharmacy chain in the Philippines serving
in 50 key
approximately 1.5 million customers
hospitals nationwide and is also the leading delivery
service drugstore in the Philippines. MedAdvisor will
provide a MedExpress branded app to support digital
medication ordering for customers. We expect
revenues from Asia to commence in 1HFY20.
UK
In August 2019, we entered the UK market through an
agreement with our first UK pharmacy chain customer,
The Day Lewis Group (“Day Lewis”). Day Lewis will
rollout PlusOne to its 270 pharmacies and a white
labelled MedAdvisor app to its 1m+ customers to
support medication ordering and management. We
are expecting revenues in the UK to begin in 2HFY20.
Executive Team Changes
We had a number of executive changes over the year.
In September 2018, we appointed Ruba El-Afifi to the
role of EGM People & Culture. Ruba has a rich history
in senior HR roles and most recently from Oracle’s
Aconex where she was GM Human Resources. This
was followed with the appointment of Victor Kovalev
an experienced Silicon Valley CTO, most recently CTO
at Redbubble (ASX:RBL) as our new CTO and Head of
Global Product. Finally, we appointed Simon Glover as
CFO. Simon is a highly regarded finance professional
who has held a number of senior finance roles in large
listed companies such as Tabcorp Holding (ASX:TAH)
and Coles Group (ASX:COL) and also brings prior
industry experience from his time at Mayne Pharma.
These significant appointments reflect MedAdvisor’s
ability to continue to attract high calibre talent and the
acceleration of its growth initiatives.
Looking ahead
There is significant potential in the domestic market to
connect more patients, pharmacies, GPs and health
programs. The traditional patient acquisition channel
– our pharmacy customers – continues to drive patient
uptake. Additionally, we continue to explore ways to
drive further patient growth via other stakeholders in
patient health, including hospitals and GPs. Growth in
take up of our Health Programs shows great promise,
and we continue to explore opportunities to bring new
program funders beyond pharma companies to
leverage our platform, such as hospitals, health
insurers and the Government.
Globally, we recognize that the potential opportunity
for MedAdvisor that is being unlocked through the
partnerships and early customer wins across the US,
Asia and UK, is many times larger than the Australian
Page | 1
business on its own. By globalizing the MedAdvisor
platform and partnering with leading local companies,
we are providing a lower cost, faster market entry and
a shorter path to revenue.
We have a bold ambition to address the global issue of
medication non-adherence and poor health literacy to
drive improved health outcomes for patients by
making medication manageable.
continued success of MedAdvisor in what promises to
be another extremely busy year.
Finally, on behalf of the Board,
I thank our
shareholders for their continued support and extend
my thanks to all our partners and customers.
Yours Sincerely
We have built a strong, experienced leadership team
across our key markets to ensure excellence in our
execution. I would like to acknowledge the work of the
Executive Team, led by Robert Read and that of all of
our employees who continue to strive to make
medication manageable
Their
commitment and effort will form the basis for the
patients.
for
Peter Bennetto
Chairman
Camberwell, 29 August 2019.
Page | 2
Summary of 2019 financial year results
Revenue breakdown by financial year
Fixed v user based operating revenue
Gross Margins by year
increase
SaaS revenue growth driven by
pharmacy
an
network, coupled with price
increases.
in
User based revenues (Messaging
and Health Program fees) has
seen strong growth from the
higher number of pharmacy and
pharma Health Programs.
Operating revenue continues to
increase strongly driven by a
growing pharmacy network and
an increased number of Health
Programs. SaaS based Annual
Recurring Revenue (ARR) is now
~$6m.
User based revenue is tracking at
~40% of total operating revenues,
up from 37% in FY18 due to the
strong growth in revenue from
Health Services Programs.
Gross Margins are stable in FY19
at ~88% creating significant
operating
the
leverage
business scales. Continued focus
on the cost of doing business will
support strong margins.
as
Page | 3
Operating and growth expenses to gross margin
Operating performance to cash
of
our
expenses
fixed
Coverage
is
operating
increasing as a result of the
growth in our margins.
in growth
investment
The
includes
expenses
the
associated with both domestic
and
international market
development.
from
collections
Cash
the
underlying business continue to
be strong and support the
growth of the business.
Page | 4
Full year profit and loss highlights
Page | 5
20192018Change$ 000's$ 000's$ 000's%RevenuesRevenues from services8,242 6,605 1,637 24.8%Total operating revenue8,242 6,605 1,637 24.8%R&D tax concession750 634 115 18.2%Government grants67 - 67 n/aNet finance income135 155 (21) (13.4%)Total Other Revenue951 790 161 20.4%Total Revenue9,193 7,394 1,799 24.3%Direct costs(1,014) (822) (192) 23.4%Gross profit7,228 5,783 1,445 25.0%Gross margin188%88%n/a0.1%Major Expenses (exc. non-cash expenses)Development(7,380) (3,662) (3,718) 101.5%Marketing & sales(4,823) (3,597) (1,227) 34.1%New market development(391) (529) 139 (26.2%)Administration(2,248) (1,608) (640) 39.8%Governance & listing costs(518) (506) (12) 2.4%Cash loss from continuing operations(7,181) (3,330) (3,851) 115.7%Depreciation & amortization(259) (197) (62) 31.6%Share based remuneration(661) (821) 159 (19.4%)One off transaction costs- (108) 108 (100.0%)Loss from continuing operations(8,101) (4,455) (3,646) 81.8%1 - margins are based on Revenues from servicesMargin growth maintained; supported by improved efficiency with technologyRevenue driven by continued growth in Pharmacy network, and user based fees, particularly Health Service ProgramsSignificant effort has been made to build capability and capacity to leverage the platform across multiple international markets.
Summary balance sheet
Summary operating cash flow
Page | 6
Normalised Quarterly Cash Flow FY17-FY19
The net operating cash flows and cash collections have been normalised by adjusting for the effects of receipt of the
R&D Tax Concession by averaging those receipts over the year to which they relate.
Page | 7
Corporate directory
Directors
Mr Peter Bennetto Non-executive Chairman
Mr Robert Read Managing Director & CEO
Mr Joshua Swinnerton Founder & Executive Director
Mr Jim Xenos Non-executive Director
Ms Sandra Hook Non-executive Director
Company secretary
Mr Carlo Campiciano
Notice of annual general meeting
Details of the annual general meeting of MedAdvisor Limited are:
At the offices of RSM Australia
Level 21, 55 Collins Street
Melbourne Vic 3000
9:00 a.m. on Tuesday 24th October 2019.
Registered office
Level 2, 971 Burke Road
Camberwell Vic 3124
Principal place of business
Level 2, 971 Burke Road
Camberwell Vic 3124
Share register
Computershare Investor Services Pty Ltd
Auditor
Lawyers
Yarra Falls
1152 Johnston Street
Abbotsford Vic 3067
RSM Australia Partners
Level 21, 55 Collins Street
Melbourne Vic 3000
HWL Ebsworth - Lawyers
Level 26, 530 Collins Street
Melbourne Vic 3000
Stock exchange listing
MedAdvisor Limited shares are listed on the Australian Securities Exchange
(ASX:MDR)
Website
www.medadvisor.com.au
Page | 8
Directors’ report
The Directors of MedAdvisor Limited (‘MedAdvisor’) present their report, together with financial statements of the
consolidated entity, being MedAdvisor Limited (‘the Company’) and its Controlled Entities (‘the Group’) for the year
ended 30 June 2019.
Directors
The names of Directors in office at any time during or since the end of the year are:
Peter Bennetto
Robert Read
Joshua Swinnerton
Jim Xenos
Sandra Hook
Non-Executive Chairman
Executive Director / Chief Executive Officer
Executive Director / Founder
Non-Executive Director
Non-Executive Director
Peter Bennetto, Non-Executive Chairman.
GAICD, SA Fin. Director since 2013.
Member of Audit and Risk Committee
Member of the People and Remuneration Committee
Peter Bennetto is an experienced company director,
with skills
in banking, corporate finance and
governance. Peter has held a number of company
director positions
in exploration, mining and
manufacturing companies listed on the ASX since
1990. Mr Bennetto has been Non-Executive
Chairman at MedAdvisor Limited (formerly Exalt
Resources Limited) since November 28, 2013.
Mr Bennetto is currently non-executive Chairman of
Ironbark Zinc Ltd and Kingwest Resources Ltd.
Robert Read, Executive Director/ CEO.
BComm(Mgt), BA(Psych), GAICD. Director since 2015.
Member of Audit and Risk Committee
Member of the People and Remuneration Committee
Robert Read has extensive commercial experience in
a wide range of businesses, including Director of
Commercial Strategy and Operations in one of the
world’s leading pharmaceutical companies, and roles
in Venture Capital and Private Equity. Robert brings a
wide range of skills to the position of CEO - in
financial
leadership,
performance
deep
understanding of the requirements to successfully
grow early stage businesses.
and marketing,
improvement
sales
and
a
Joshua Swinnerton, Executive Director/ Founder.
MEI, GradCert Eng., BE, BCS(Hons). Director since
2015.
Joshua Swinnerton has extensive experience leading
and managing sizeable IT ventures, both within large
companies, as a consultant, and as the technical and
operational lead of start-up companies. Prior to
founding MedAdvisor, Josh led a technology start-up
which he also founded and sold into the US as well as
raising funds in the US for the company’s expansion
and managed software development. During this
time Mr Swinnerton gained valuable experience in
bridging the gap between innovative technology and
business objectives. Josh also has extensive skills in
building and managing exceptional development
teams.
Jim Xenos, Non-Executive Director.
BSc, DipEd, AFAIM, GAICD. Director since 2015.
Member of Audit and Risk Committee
Chair of the People and Remuneration Committee
Jim Xenos brings to the board a wealth of
pharmaceuticals
industry experience and market
insight, forged over 25+ years leading highly successful
teams to drive strong commercial outcomes.
He has a track record of delivering market share and
profit growth across national and multinational
corporations by creating impactful brand and portfolio
strategies, and by introducing new product offerings
that leverage innovative go-to market platforms in
highly competitive industry categories.
In addition to his extensive industry knowledge, Mr
Xenos’ brings to the role a sharp strategic mindset,
collaborative approach and a single-minded focus on
value creation.
Sandra Hook, Non-Executive Director.
GAICD. Director since 2016.
Chair of Audit and Risk Committee
Member of the People and Remuneration Committee
Sandra Hook has 25+ years’ experience developing
and implementing commercially successful business
and brands driving growth and leading change.
Page | 9
Directors’ report - continued
Sandra has a track record in delivering customer-
centred business transformation and transitioning
traditional
rapidly evolving
environments.
organisations
in
brings
extensive operational,
Sandra
financial
management and strategic experience built over a
includes CEO, COO, GM, Marketing
career which
Director and Snr Brand Manager with some of
Australia’s largest media companies including News
Limited, Foxtel, Federal Publishing Company, Murdoch
Magazines and Fairfax. She brings a strong focus on
customer-centric growth and digital innovation at
Board level.
Since 2000 she has served as a non-executive director
on listed, public and private companies, and
government bodies.
and marketing
listed digital,
Sandra is currently director of ASX
technology
communications
companies: RXP Services Ltd and IVE Group Ltd, as well
as .au Domain Administration Ltd and the Sydney Fish
Market Ltd. She is a trustee of the Sydney Harbour
Federation Trust.
Company secretary
Carlo Campiciano, Company Secretary/ CFO
MEI, GradDip(Comp), Bbus(Acc), GIA(cert), MIPA.
Carlo Campiciano is a qualified accountant with extensive experience working with business on a wide range of areas
including taxation, finance, operations, planning, operational and financial strategy. Mr Campiciano commenced his
career with Coopers & Lybrand where he completed his Professional Year of Study which qualified him for admittance
to the Institute of Chartered Accountants before moving onto roles in professional services firms as well as roles in
industry which extended both his technical as well as practical business skills. Mr Campiciano was a Director of
MedAdvisor International Pty Ltd prior to the relisting of MedAdvisor Limited and was the CFO from 2012 until June
30, 2019.
Directors’ meetings
Page | 10
Directors’ report - continued
Principal activities
The principal activities of the Entity have continued to be the development and deployment of the MedAdvisor
medication and adherence platform. The MedAdvisor platform is focused on improving health outcomes by
connecting health professionals with their patients using mobile and web technologies.
Operating results
During the year, the Company reported a net loss of $8,101,385 (2018 $4,454,211). Operating revenue totaled
$8,241,993, growing 25% on the prior financial year (2018 $6,604,762).
Dividends
No dividends have been paid or declared by the Company since the beginning of the year.
Review of operations
MedAdvisor’s core purpose is to tackle the global issue of medication non-adherence and poor health literacy to drive
improved health outcomes for patients by making medication manageable. Improving adherence and health literacy
creates benefits for all MedAdvisor’s stakeholders; for patients, improved health outcomes, for pharmacy and
pharmaceutical companies, increased revenue and for healthcare payors such as government, health insurers and
hospitals, reduced health costs.
Delivering on this core purpose, MedAdvisor derives revenue from three key customer segments:
1. Pharmacies, that pay SaaS fees (plus messaging fees) for a license to PlusOne, a pharmacy software solution
that digitally connects a pharmacy to its patients via an App, SMS and web/email and supports the delivery
of a range of health programs and services (‘Health Programs’);
2. Pharmaceutical companies, that pay a per patient fee for the delivery of Health Programs directly to patients
or in-pharmacy; and
3. Patients, who get free access to the App, SMS and web/email services (‘MedAdvisor App’) and can pay for
premium services such as certain GP-related services.
Customer Type: Pharmacy
Product: PlusOne
The global landscape for the pharmacy sector is experiencing significant change. In a range of markets, revenue
derived from the traditional source of medication dispensing has been falling for some time, resulting in increased
pressure to offer customers value-added health services and programs. Competitive pressure from non-traditional,
new market entrants like Amazon is also driving consumer expectations around convenience and digital experience
that raise the bar for the sector.
PlusOne offers pharmacies a Software-as-a-Service solution that empowers them to digitally connect to their patients,
automate medication reminders, and offer a range of ordering and medication related services. In addition to allowing
patients to “click & collect” their medication, pharmacies use PlusOne to alert them to health programs and services
funded by the government (through 6CPA) and pharmaceutical companies (through MedAdvisor) that are relevant
and appropriate for their patients. Patients can be enrolled, a record of the delivery of the program or service
streamlined, and any fees earned by the pharmacy automatically claimed.
Importantly, pharmacies using PlusOne report higher customer loyalty with less than 3% of MedAdvisor App users
changing pharmacy within the App, improved adherence for their connected patients (+20%), and the simpler
Page | 11
Directors’ report - continued
mechanism for services delivery means time savings that lead to more services and more revenue.
Customer Type: Pharmaceutical Companies
Products: Health Programs
The World Health Organisation (“WHO”) estimates that medical adherence to long term therapies in developed
nations is approximately 50%, and closing the gap represents the largest driver of the avoidable health costs that
ensue, impacting the funders of health care including governments, health insurers and hospitals. In addition, low
adherence costs pharmaceutical companies more than $630 billion1 in revenue each year.
MedAdvisor’s Health Programs offer pharmaceutical companies a platform for distribution of direct to patient and in-
pharmacy programs to large, aggregated, hard to reach audiences to communicate information to drive quality use of
medicine, health literacy resulting in improved adherence, and seek to reduce the $630B loss in revenue. MedAdvisor
is working toward becoming a global leader in the distribution of Health Programs, with its global reach expanding
dramatically in FY19 through a combination of its partnership with Adheris, its joint venture with Zuellig Pharma, and
its UK market entry.
MedAdvisor offers several Health Program types to meet pharmaceutical companies’ requirements, including digital
adherence, healthcare provider intervention, patient awareness, clinical trial recruitment, and patient surveys. Fees
are charged on a per patient basis. The advantage for global pharmaceutical companies of working through
MedAdvisor is the aggregation of hard to reach audiences across multiple pharmacy chains that results in lower
overhead, centralized compliance processes, the range of Health Program types, and a proven model for improving
patient adherence.
Customer Type: Patients
Product: MedAdvisor App
In each of the markets that MedAdvisor operates in, a large part of the population (typically upwards of 50%) suffers
from at least one chronic condition and is on at least one long-term medication. MedAdvisor App patients report
feeling more in control of their health and medication, being more organized around their medication and saving
significant time in the ordering process. The added peace of mind that comes from having easy access to medication
history for those in more frequent interactions with the health system cannot be underestimated.
The MedAdvisor App provides a digital connection for patients to their pharmacist to support them in their medication
journey. Comprising important information regarding their medication, the ability to pre-order when required and
added benefits including dosage reminders, a GP script renewal service and carer mode that allows users to take care
of others.
Domestic Business
MedAdvisor’s Australian business represents a strong, growing core for the company. At the close of FY19,
MedAdvisor had over 3,300 pharmacies using PlusOne (55% of the Australian market) to digitally connect to over 1.2
million patients and to process in excess of $300m worth of medication orders. In addition, MedAdvisor’s pharmacy
network increased the number of Federal Government funded, 6CPA professional services in FY19 by over 76% and
MedAdvisor delivered an additional 58 Health Programs funded by Pharmaceutical Companies, up from 30 in FY18.
1 https://www.rdmag.com/news/2016/11/medication-nonadherence-costs-billions-lost-revenue
Page | 12
Directors’ report - continued
Revenue increased by 25% year on year overall.
Average Revenue Per Pharmacy
Revenue per pharmacy has increased at a compound annual
growth rate (“CAGR”) of ~37% over the past 3 years with SaaS
license and messaging fees averaging ~$175/month in FY19.
Retention of pharmacies has averaged >97%, indicative of the
strong engagement with the software and the positive return on
investment. On average, pharmacies earn >8x ROI on their
investment in PlusOne through the increased revenue from
prescriptions and fees generated from services.
Revenue from Health Programs grew 48% with revenue per pharma
company increasing 2.6x on average over three years. This
increase demonstrates the impact of repeat Health Program
funding via pharmaceutical companies evidently satisfied with the
return on investment.
Growth in Health Program Revenue from
a Pharma Company Over Time
These results demonstrate the strength of the core domestic business, and the Australian market continues to show
material opportunities for growth through across a range of key metrics.
First, with an estimated population of chronic patients estimated at up to 12 million nationally, growth of the
MedAdvisor App user base remains a key focus, with pharmacy still a primary channel for customer acquisition.
Additionally, MedAdvisor is exploring other viable, scalable of new customer app sign-ups, including via GPs, hospitals
and direct-to-consumer.
Second, building on its dominant position and the industry leading nature of PlusOne, MedAdvisor can grow market
share with community pharmacies. PlusOne is perfectly positioned to assist pharmacy with the increasing emphasis
on in-pharmacy services. For example, in FY19, MedAdvisor network pharmacies delivered just under 300,000 flu
vaccinations, a 236% increase on prior year and MedAdvisor continues to offer the industry leading solution for
pharmacists to offer, deliver and claim for in-pharmacy services.
Third, there remains significant potential in Australia for MedAdvisor in the delivery of Health Programs. Revenue
from pharmaceutical companies funding Health Programs grew significantly in FY19 to $1m. Additionally, MedAdvisor
is looking toward other potential funders of Health Programs, including private health insurers, hospitals and
government.
International Growth
FY19 has been a seminal year for MedAdvisor’s expansion overseas, with commercial partnerships and/or new
customers acquired in the US, UK and South-East Asia. With investment in moving to a global product suite,
MedAdvisor’s globally leading platform will move from generating revenue in one to four geographic markets in FY20.
USA
The US represents a highly attractive market to MedAdvisor given it is the largest pharmaceutical market in the
Page | 13
Directors’ report - continued
world, with a well-developed community pharmacy sector comprising large chains and banners representing over
60% market share of the total pool of 60,000 pharmacies. MedAdvisor has established a team that has deep local
knowledge, expertise and relationships within the US healthcare sector, including MedAdvisor founder, Josh
Swinnerton, who relocated to support the rollout.
In March 2019, MedAdvisor signed an initial 12-month agreement with Adheris Health, the leading provider of
dynamic patient adherence and engagement solutions to US biopharmaceutical customers. Adheris Health has built
a participating network of 26,000+ pharmacies that account for ~197m US patients. They also bring relationships
with the top 100 US retail-dispensed branded pharmaceutical manufacturers, including the US arms of many of
MedAdvisor’s existing Australian clients.
The advantage of the Adheris Health partnership for MedAdvisor is that it can offer Health Programs via Adheris
Health in the US without the need for US pharmacy chains to license and install PlusOne. This reduces the
requirements for integration with multiple dispense vendors and has allowed the team to focus on the Health
Program requirements in the largest pharmaceutical market in the world, whilst keeping the door open for the sale
of PlusOne in the future.
Under the agreement, Adheris Health will promote and jointly sell MedAdvisor powered Health Programs in the US
to its existing pharmaceutical clients as an extension of its suite of Health Program solutions. Revenue is expected to
come online in 1H20.
Asia
During 1H19, MedAdvisor announced a 50/50 joint venture with Zuellig Pharma. Zuellig Pharma is one of the largest
healthcare services groups in Asia. Started almost a hundred years ago, it has grown to become a US$13 billion
business covering 13 markets with over 10,000 employees, serving over 350,000 medical facilities and working with
over 1,000 clients, including the top 20 pharmaceutical companies in the world.
The joint venture will operate from Singapore, with Zuellig Pharma to commercialise MedAdvisor’s medication
management platform. In return, MedAdvisor will license its core intellectual property to the JV on an exclusive royalty
free basis and develop localized versions of its platform. In May 2019, MedAdvisor announced that it had signed its
first customer, MedExpress Drugstores in the Philippines. MedExpress is the leading hospital out-patient pharmacy in
the Philippines, serving over 1.5million people across 50 hospitals in the Philippines. Revenue is expected to come
online in 1H20.
UK
The UK represents a highly attractive market for MedAdvisor’s platform. There are 14,000 pharmacies with large
corporatized ownership groups and independents, as well as an NHS infrastructure that significantly reduces the
integration points required to access consented patient medication data. Added to this is a population of 66 million,
and with 54% of people aged over 65 living with two or more chronic medical conditions, making MedAdvisor a
powerful platform for the market.
MedAdvisor secured its first customer in the UK in August 2019 with the signing of Day Lewis Pharmacy Group (‘Day
Lewis’) - one of the largest independent pharmacy chains in the UK owning over 270 pharmacies, and servicing over
1 million customers. Day Lewis will license PlusOne and promote and distribute a Day Lewis branded version of the
MedAdvisor consumer app to its customers for medication ordering and management. Rollout of the MedAdvisor
platform across Day Lewis pharmacies will take place during the Q3 FY20.
New management appointments
During the year, MedAdvisor made several new appointments to the Executive team. In February, Victor Kovalev,
was appointed as CTO and Global Head of Product. Victor Kovalev is an experienced Silicon Valley CTO, and prior to
Page | 14
Directors’ report - continued
joining MedAdvisor was CTO at Redbubble (ASX:RBL). This appointment followed the appointment in late last year of
Ruba El-Afifi former EGM of HR at Aconex as EGM People & Culture as GM of People and Culture. Following the
retirement of CFO, Carlo Campiciano, in August 2019, Simon Glover was appointed as the new CFO. Simon is a highly
regarded finance professional who has held a number of senior finance roles in large listed companies such as
Tabcorp Holding (ASX:TAH) and Coles Group (ASX:COL) and also brings prior industry experience from his time at
Mayne Pharma. These significant appointments reflect MedAdvisor’s ability to attract high calibre talent and the
acceleration of its growth initiatives.
Financial position
The Group has $4,400,719 plus $127,022 in cash on deposit as security, bringing a total cash balance of $4,527,741
as of 30 June 2019 following a net cash decrease of $6,074,058 for the year.
The net assets of the Group at 30 June 2019 were $8,644,281, a decrease in net assets of $6,523,641 from 30 June
2018.
Proceedings
No person has applied for leave of Court to bring proceedings on behalf of the Group or intervene in any proceedings
to which the Group is a party for the purpose of taking responsibility on behalf of the Group for all or any part of
those proceedings. The Group was not a party to any such proceedings in the period.
Matters subsequent to the end of the financial year
There have been no other matters or circumstances which have arisen since the end of the financial period that
significantly affected, or may significantly affect the operations of the Entity, the results of those operations or the
state of affairs of the Entity in future years.
Auditor’s independence declaration
In accordance with section 307C of the Corporations Act 2001 the auditor’s independence declaration for the year
ended 30 June 2019 has been received and can be found on page 23 of the Annual Report and forms part of this
report.
Unissued ordinary shares under option
Page | 15
Remuneration report - audited
The Directors of MedAdvisor Limited (the Group) present the Remuneration Report for Non-Executive Directors,
Executive Directors and other Key Management Personnel, prepared in accordance with the Corporations Act 2001
and the Corporations Regulations 2001 Remuneration Philosophy.
The Remuneration Report is set out under the following main headings:
a. Principles used to determine the nature and amount of remuneration
b. Details of remuneration
c. Service agreements
d. Share-based remuneration; and
e. Other information
a. Principles used to determine the nature and amount of remuneration
The principles of the Group’s executive strategy and supporting incentive programs and frameworks are:
•
•
•
to align rewards to business outcomes that deliver value to shareholders;
to drive a high-performance culture by setting challenging objectives and rewarding high performing
individuals; and
to ensure remuneration is competitive in the relevant employment market place to support the attraction,
motivation and retention of executive talent.
MedAdvisor Limited has structured a remuneration framework that is market competitive and complementary to the
reward strategy of the Group. The remuneration structure that has been adopted by the Group consists of the
following components:
•
•
•
fixed remuneration being annual salary;
short term incentives, being bonuses; and
long term incentives, being employee share schemes.
The payment of bonuses, share options and other incentive payments are reviewed by the Board prior to approval
by the Board annually as part of the review of executive remuneration. All bonuses, options and incentives must be
linked to pre-determined performance criteria.
Short Term Incentive (STI) and Long-Term Incentive (LTI)
MedAdvisor performance measures involve the use of annual performance objectives, metrics, performance
appraisals and continuing emphasis on living the Company values. The performance measures are set annually after
consultation with the Directors and executives and are specifically tailored to the areas where each executive has a
level of control. The measures target areas the Board believes hold the greatest potential for expansion and profit
and cover financial and non-financial measures.
The Key Performance Indicators (KPI’s) for the Executive Team are summarised as follows:
Performance areas
•
•
financial – revenues and operating results; and
non-financial – strategic goals set for each business unit based on job descriptions
The STI and LTI Program’s incorporate both cash and share-based components for the Executive Team and other
employees. The Board may, at its discretion, award bonuses for exceptional performance in relation to each person’s
pre-agreed KPIs.
Page | 16
Remuneration report –audited continued
b. Details of remuneration
Mr Read’s performance linked Share Based Entitlements are in accordance with his Employment Agreement dated 30 June 2015 which were
disclosed in the Company’s Prospectus dated 8 September 2015. These Share Based Entitlements are brought to account based on a probability
of all the performance milestones under his Employment Agreement being achieved. During the financial year 11,000,000 Read Rights vested
and 15,000,000 Read Rights lapsed based on the agreed milestones. The value brought to account of the Vested Read Rights in the current
year; net of the value brought to account in previous years for lapsed options is $7,398, (2018 $81,072).
1 Share based entitlements have been measured at fair value on grant date determined in accordance with the Binomial or Black- Scholes option
pricing model.
The proportion of the cash bonus paid/payable or forfeited is as follows:
Page | 17
Remuneration report –audited continued
The relative proportions of remuneration that are linked to performance and those that are fixed are as follows:
c. Service agreements
Remuneration and other terms of employment for the Executive Directors and other Key Management Personnel
are formalised in a Service Agreement. The major provisions of the agreements relating to remuneration are set out
below:
Note: Base salary noted above is the current base salary and is exclusive of superannuation which under the
applicable service agreements is capped in accordance with the maximum superannuation contribution base for
superannuation guarantee purposes.
The remuneration of non-executive Directors is set by the Board at a level that provides the Board with the ability to
attract and retain directors of the highest calibre whilst incurring a cost that is acceptable to shareholders. At the
Annual General Meeting held on 18 December 2015 shareholders approved aggregate remuneration of non-
executive directors of $350,000 per annum.
The amount each non-executive director is remunerated is set by the Board based on the recommendation from the
People and Remuneration Committee. Individual remuneration is set having regard to the director’s experience and
their role on the Board and Committees.
d. Share-based remuneration
MedAdvisor employee incentive option plan
All options refer to options over ordinary shares of the Company, which are exercisable at no cost on a one-for-one
basis under the terms of the Employee Share Option Plan that was approved by shareholders at the 2015 annual
general meeting.
Options granted to employees under the MedAdvisor Employee Incentive Option Plan will vest subject to the service
period and performance milestone conditions in the grant of Options in accordance with the plan. Unvested options
will expire on the termination of the individual’s employment; vested options will expire on the expiry date, which is
15 years.
Page | 18
Remuneration report –audited continued
Read Rights
Rights were issued to Mr Read under his employment agreement dated 1 July 2015 and were exercisable subject to
meeting the following conditions:
• 5 million for continuous employment (Employment Rights) over a 5-year period from the date of his
•
employment with MedAdvisor International Pty Ltd
37.5 million on achievement of predetermined revenue, activated patients and active medical practitioner
targets (Performance Rights) within 3 years from the date of relisting of the Company on the Australian
Securities Exchange being 1 December 2015.
Employment Rights
4 million of Mr Read’s Employment Rights have vested as at 30 June 2019, and the remaining 1 million are due to
vest on 30 June 2020 on the condition that Mr Read is employed by the Company at the vesting date.
Performance Rights
Of the 37.5 million Performance Rights, 15 million lapsed on 1 December 2018 and 22.5 million had vested on
achievement of the predetermined milestones as of 1 December 2018 as follows:
Of the total of 26.5 million Read Rights that have vested (4 million Employment Rights and 22.5 million Performance
Rights), Mr Read has exercised a total of 12 million Read Rights (7 million in September 2017 and 5 million in May
2019), 14.5 million Read Rights that have vested but not exercised as at 30 June 2019.
All of the Read Rights refer to rights over ordinary shares of the Company, which are exercisable on a one-for-one
basis at no cost under the terms of the Mr Read’s employment agreement.
Performance Incentives for year ended 30 June 2020
The Board has approved a performance-based incentive plan for Mr Read (CEO) for financial year 2020 via an
allocation of 12 million Employee Incentive Options under the MedAdvisor Employee Incentive Plan. The options will
vest based on the achievement of a number of pre-determined performance targets across international expansion,
product execution, people and culture metrics and share price targets. The vesting of the performance options will
be at the discretion of the Board.
Bonuses included in remuneration
During the 2018 financial year Mr Read was paid his short-term incentive cash bonus of $30,000 which was accrued
at the end of the previous financial year. There were no bonuses paid and or payable in the 2019 financial year.
Other information
Options held by directors and key management personnel
The number of options and rights to acquire shares in the Company held during the 2019 reporting period by each
of the directors and key management personnel of the Group; including their related parties are set out below.
Page | 19
Remuneration report –audited continued
1Read Rights
Shares held by directors and key management personnel
Ordinary Shares
The number of ordinary shares in the Company held during the 2019 reporting period by each of the directors and
key management personnel of the Group; including their related parties are set out below.
a 8,166,667 shares of Mr Read’s holding is subject to voluntary escrow until 1 December 2018.
b 145,062,602 shares of Mr Swinnerton’s holding is subject to voluntary escrow until 1 December 2018.
c 126,236,062 shares of Mr Xenos’ holding is subject to voluntary escrow until 1 December 2018.
d 21,506,562 shares of Mr Campiciano’s holding is subject to voluntary escrow until 1 December 2018.
Page | 20
Remuneration report –audited continued
Founder Performance Shares
There were no Founder Performance Shares in the Company held during the 2019 reporting period. The following
Founder Performance Shares held by each of the directors and key management personnel of the Group; including
their related parties that converted to Ordinary shares in the 2018 reporting period are set out below.
Founder Performance Shares converted to ordinary shares upon satisfaction of both of the following milestones in
October 2017:
-
-
50% of the Founder Performance Shares shall convert upon the “MedAdvisor Platform” being activated at
2,500 pharmacies within a period of 2 years from the issue of the Founder Performance Shares; and
50% of the Founder Performance Shares shall convert upon the Company receiving annualised revenue
from the MedAdvisor business (calculated over two consecutive calendar quarters) of no less than
$5,000,000, within a period of 3 years from the issue of the Founder Performance Shares.
Other transactions with directors and key management personnel:
- During 2019 the Group used the services of NostraData Pty Ltd of which Mr Jim Xenos is a director and has
significant influence. The amounts billed relate to the provision of Data Services by NostraData Pty Ltd and
amounted to $140,825 (2017 $120,345).
End of audited Remuneration Report
Additional information
The earnings of the group since the incorporation of MedAdvisor International Pty Ltd are summarized below:
Indemnities given to, and insurance premiums paid for officers
The company has indemnified the directors and executives of the company for costs incurred, in their capacity as a
director or executive, for which they may be held personally liable, except where there is a lack of good faith.
Page | 21
Additional information - continued
During the financial year, the company paid a premium in respect of a contract to insure the directors and executives
of the company against a liability to the extent permitted by the Corporations Act 2001. The contract of insurance
prohibits disclosure of the nature of the liability and the amount of the premium.
Indemnities and insurance premiums of auditor
The company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of
the company or any related entity against a liability incurred by the auditor.
During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the
company or any related entity.
Non-audit services
During the year, RSM Australia Partners, the Company’s auditors, did not perform any other services in addition to
their statutory audit duties.
Details of the amounts paid to the auditors of the Company, RSM Australia Partners, and its related practices for audit
services provided during the year are set out in Note 11 to the financial statements.
Proceedings on behalf of the Company
No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on
behalf of the Company, or to intervene in any proceedings to which the Company is a party, for the purpose of taking
responsibility on behalf of the Company for all or part of those proceedings.
Auditor’s independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set
out immediately after this directors' report.
Auditor
RSM Australia Partners continues in office in accordance with section 327 of the Corporations Act 2001.
This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations
Act 2001.
On behalf of the directors,
Peter Bennetto
Chairman
29 August 2019
Camberwell, VIC.
Page | 22
AUDITOR’S INDEPENDENCE DECLARATION
As lead auditor for the audit of the financial report MedAdvisor Limited for the year ended 30 June 2019, I declare
that, to the best of my knowledge and belief, there have been no contraventions of:
(i)
(ii)
the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and
any applicable code of professional conduct in relation to the audit.
RSM AUSTRALIA PARTNERS
P A RANSOM
Partner
Dated: 29 August 2019
Melbourne, Victoria
Page | 23
Corporate governance statement
Corporate governance
The Board is committed to achieving and demonstrating the highest standards of corporate governance. As such,
MedAdvisor Limited and its Controlled Entities (‘the Group’) have adopted the third edition of the Corporate
Governance Principles and Recommendations which was released by the ASX Corporate Governance Council on 27
March 2014 and became effective for financial years beginning on or after 1 July 2014.
The Group’s Corporate Governance Statement for the financial year ending 30 June 2019 is dated as at 30 June 2019
and date of last review and Board approval was on 23 August 2019. The Corporate Governance Statement is
available on MedAdvisor’s website at:
http://medadvisor.com.au/Investors/CorporateDirectory#governance-policies
Page | 24
Consolidated financial report for the year ended 30 June 2019
Page | 25
MEDADVISOR LIMITED
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR YEAR ENDED 30 JUNE 2019
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction
with the accompanying notes.
Page | 26
MEDADVISOR LIMITED
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2019
The above consolidated statement of financial position should be read in conjunction with the accompanying notes.
Page | 27
MEDADVISOR LIMITED
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR YEAR ENDED 30 JUNE 2019
The above consolidated statement changes in equity should be read in conjunction with the accompanying
notes.
Page | 28
MEDADVISOR LIMITED
CONSOLIDATED STATEMENT OF CASHFLOWS
FOR YEAR ENDED 30 JUNE 2019
The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.
Page | 29
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 1: Statement of Significant Accounting Policies
The financial statements cover the Company of MedAdvisor Limited. MedAdvisor Limited is a listed public
company limited by shares, incorporated and domiciled in Australia.
The financial statements were authorized for issue on the 29 August 2019 by the Directors of the Company.
Basis of preparation
The financial statements are general purpose financial statements that have been prepared in accordance with
Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the
Australian Accounting Standards Board (AASB) and the Corporations Act 2001. The Company is a for-profit entity for
financial reporting purposes under Australian Accounting Standards.
Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial
statements containing relevant and reliable information about transactions, events and conditions. Compliance
with Australian Accounting Standards ensures that the financial statements and notes also comply with International
Financial Reporting Standards as issued by the IASB. Material accounting policies adopted in the preparation of
these financial statements are presented below and have been consistently applied unless otherwise stated.
The financial statements have been prepared on an accruals basis and are based on historical costs, modified, where
applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.
Accounting Policies
(a)
Principles of Consolidation
The consolidated financial statements incorporate all of the assets, liabilities and results of the parent
MedAdvisor Limited and all of the subsidiaries. Subsidiaries are entities the parent controls. The parent controls an
entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability
to affect those returns through its power over the entity. A list of controlled entities is contained in Note 6 of the
Financial Statements.
The assets, liabilities and results of all subsidiaries are fully consolidated into the financial statements of the Group from
the date on which control is obtained by the Group. The consolidation of a subsidiary is discontinued from the date
that control ceases. Intercompany transactions, balances and unrealised gains or losses on transactions between
Group entities are fully eliminated on consolidation. Accounting policies of subsidiaries have been changed and
adjustments made where necessary to ensure uniformity of the accounting policies adopted by the Group.
Equity interests in a subsidiary not attributable, directly or indirectly, to the Group are presented as “non-controlling
interests”. The Group initially recognises non-controlling interests that are present ownership interests
in
subsidiaries and are entitled to a proportionate share of the subsidiary’s net assets on liquidation at either fair
value or at the non-controlling interests’ proportionate share of the subsidiary’s net assets. Subsequent to initial
recognition, non-controlling interests are attributed their share of profit or loss and each component of other
comprehensive income. Non-controlling interests are shown separately within the equity section of the statement
of financial position and statement of comprehensive income.
(b)
Operating segments
Operating segments are presented using the 'management approach', where the information presented is on the
same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is
responsible for the allocation of resources to operating segments and assessing their performance.
Page | 30
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
(c)
Revenue recognition
The consolidated entity recognises revenue as follows:
Revenue from contracts with customers
Revenue is recognised at an amount that reflects the consideration to which the consolidated entity is expected to
be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the
consolidated entity: identifies the contract with a customer; identifies the performance obligations in the contract;
determines the transaction price which takes into account estimates of variable consideration and the time value of
money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-
alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each
performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services
promised.
Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as
discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent
events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The
measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised
to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will
not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is
subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund
liability.
License fees
License fees are charged for the use of the MedAdvisor platform and the revenue recognized at the point at which
the customer has agreed to the terms and conditions of use of the platform and installs the interface on their
computer equipment and is able to benefit from and be rewarded for the use of the platform.
Rendering of services
Rendering of services revenue from computer maintenance fees is recognised by reference to the stage of
completion of the contracts. Stage of completion is measured by reference to labour hours incurred to date as a
percentage of total estimated labour hours for each contract. Where the contract outcome cannot be reliably
estimated, revenue is only recognised to the extent of the recoverable costs incurred to date.
Interest
Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating
the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective
interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the
financial asset to the net carrying amount of the financial asset.
Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.
(d)
Income tax
The income tax expense (revenue) for the period comprises current income tax expense (income) and deferred tax
expense (income).
Page | 31
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Current income tax expense charged to the profit or loss is the tax payable on taxable income calculated using
applicable income tax rates enacted, or substantially enacted, as at the end of the reporting period. Current tax
liabilities (assets) are therefore measured at the amounts expected to be paid to (recovered from) the relevant
taxation authority.
Deferred income tax expense reflects movements in deferred tax asset and deferred tax liability balances during the
year as well unused tax losses.
Current and deferred income tax expense (income) is charged or credited directly to equity instead of the profit or
loss when the tax relates to items that are credited or charged directly to equity.
Deferred tax assets and liabilities are ascertained based on temporary differences arising between the tax bases of
assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets also result where
amounts have been fully expensed but future tax deductions are available. No deferred income tax will be recognised
from the initial recognition of an asset or liability, excluding a business combination, where there is no effect on
accounting or taxable profit or loss.
Deferred tax assets and liabilities are calculated at the tax rates that are expected to apply to the period when the
asset is realised or the liability is settled, based on tax rates enacted or substantively enacted at the end of the
reporting period. Their measurement also reflects the manner in which management expects to recover or settle
the carrying amount of the related asset or liability.
Deferred tax assets relating to temporary differences and unused tax losses are recognised only to the extent that it is
probable that future taxable profit will be available against which the benefits of the deferred tax asset can be utilised.
Where temporary differences exist in relation to investments in subsidiaries, branches, associates, and joint
ventures, deferred tax assets and liabilities are not recognised where the timing of the reversal of the temporary
difference can be controlled and it is not probable that the reversal will occur in the foreseeable future.
Current tax assets and liabilities are offset where a legally enforceable right of set-off exists and it is intended that net
settlement or simultaneous realisation and settlement of the respective asset and liability will occur. Deferred tax
assets and liabilities are offset where a legally enforceable right of set-off exists, the deferred tax assets and liabilities
relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable
entities where it is intended that net settlement or simultaneous realisation and settlement of the respective asset and
liability will occur in future periods in which significant amounts of deferred tax assets or liabilities are expected to
be recovered or settled.
(e)
Current and non-current classification
Assets and liabilities are presented in the statement of financial position based on current and non-current classification.
An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the
consolidated entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realized within
12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used
to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.
A liability is classified as current when: it is either expected to be settled in the consolidated entity's normal operating cycle; it
is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no
unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities
are classified as non-current.
Deferred tax assets and liabilities are always classified as non-current.
Page | 32
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
(f)
Cash and cash equivalents
Cash and cash equivalents includes cash on hand, deposits held at call with banks and other short-term highly liquid
investments with original maturities of three months or less.
(g)
Trade and other receivables
Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the
effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for
settlement within 30 days.
The consolidated entity has applied the simplified approach to measuring expected credit losses, which uses a
lifetime expected loss allowance to measure the expected credit losses, trade receivables have been grouped based
on days overdue.
Other receivables are recognised at amortised cost, less any allowance for expected credit losses.
(h)
Work in progress
Work in progress on services contract’s in progress comprises the cost of labour directly related to the performance
of the contract plus any other direct costs incurred in delivering the contract services.
(i)
Plant and equipment
Plant and equipment are measured on the cost basis and therefore carried at cost less accumulated depreciation and
any accumulated impairment. In the event the carrying amount of plant and equipment is greater than the estimated
recoverable amount, the carrying amount is written down immediately to the estimated recoverable amount and
impairment losses are recognised either in profit or loss or as a revaluation decrease if the impairment losses relate
to a revalued asset. A formal assessment of recoverable amount is made when impairment indicators are present
(refer to Note 1 (l) for details of impairment).
The carrying amount of plant and equipment is reviewed annually by directors to ensure it is not in excess of the
recoverable amount from these assets. The recoverable amount is assessed on the basis of the expected net cash
flows that will be received from the asset’s employment and subsequent disposal. The expected net cash flows have
been discounted to their present values in determining recoverable amounts.
Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only
when it is probable that future economic benefits associated with the item will flow to the Company and the cost of
the item can be measured reliably. All other repairs and maintenance are recognised as expenses in profit or loss
during the financial period in which they are incurred.
Depreciation
The depreciable amount of all fixed assets including buildings and capitalised lease assets, but excluding freehold land,
is depreciated over the asset’s useful life to the Company commencing from the time the asset is held ready for use.
Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the
estimated useful lives of the improvements.
The depreciation rates and method of deprecation is as follows:
• Office equipment – diminishing value at 30% p.a.
• Office furniture – straight line at 20% p.a.
•
Leasehold improvements – straight line over the unexpired period of the lease
Page | 33
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
(j)
Leases
The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement
and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset
or assets and the arrangement conveys a right to use the asset.
A distinction is made between finance leases, which effectively transfer from the lessor to the lessee substantially all
the risks and benefits incidental to the ownership of leased assets, and operating leases, under which the lessor
effectively retains substantially all such risks and benefits.
Finance leases are capitalised. A lease asset and liability are established at the fair value of the leased assets, or if
lower, the present value of minimum lease payments. Lease payments are allocated between the principal
component of the lease liability and the finance costs, so as to achieve a constant rate of interest on the remaining
balance of the liability.
Leased assets acquired under a finance lease are depreciated over the asset's useful life or over the shorter of the
asset's useful life and the lease term if there is no reasonable certainty that the consolidated entity will obtain
ownership at the end of the lease term.
Operating lease payments, net of any incentives received from the lessor, are charged to profit or loss on a straight-
line basis.
(k)
Intangible assets
Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair
value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite
life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life
intangible assets are subsequently measured at cost less amortization and any impairment. The gains or losses
recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference
between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite
life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are
accounted for prospectively by changing the amortization method or period.
Goodwill
Goodwill arises on the acquisition of a business. Goodwill is not amortised. Instead, goodwill is tested annually for
impairment, or more frequently if events or changes in circumstances indicate that it might be impaired, and is
carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit or loss and are
not subsequently reversed.
Patents and trademarks
Significant costs associated with patents and trademarks are deferred and amortised on a straight-line basis over the
period of their expected benefit, being their finite life of 10 years.
(l)
Impairment of assets
At the end of each reporting period, the Company assesses whether there is any indication that an asset may be
impaired. The assessment will include the consideration of external and internal sources of information including
dividends received from subsidiaries, associates or jointly controlled entities deemed to be out of pre-acquisition
profits. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable
amount of the asset, being the higher of the asset’s fair value less costs to sell and value in use, to the asset’s
Page | 34
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
carrying amount. Any excess of the asset’s carrying amount over its recoverable amount is recognised immediately
in profit or loss, unless the asset is carried at a revalued amount in accordance with another Standard (e.g. in
accordance with the revaluation model in AASB 116: Property, Plant and Equipment). Any impairment loss of a
revalued asset is treated as a revaluation decrease in accordance with that other Standard.
Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the
recoverable amount of the cash-generating unit to which the asset belongs.
Impairment testing is performed annually for goodwill, intangible assets with indefinite lives and intangible assets
not yet available for use.
(m)
Trade and other payables
These amounts represent liabilities for goods and services provided to the consolidated entity prior to the end of the
financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not
discounted. The amounts are unsecured and are usually paid within 30 days of recognition.
(n)
Provisions
Provisions are recognised when the consolidated entity has a present (legal or constructive) obligation as a result of
a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate
can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the
consideration required to settle the present obligation at the reporting date, taking into account the risks and
uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a
current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is
recognised as a finance cost.
(o)
Employee benefits
Short-term employee benefits
Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to
be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when
the liabilities are settled.
Other long-term employee benefits
The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting
date are measured as the present value of expected future payments to be made in respect of services provided by
employees up to the reporting date. Consideration is given to expected future wage and salary levels, experience of
employee departures and periods of service. Expected future payments are discounted using market yields at the
reporting date on corporate bonds with terms to maturity and currency that match, as closely as possible, the
estimated future cash outflows.
Share-based payments
Equity-settled and cash-settled share-based compensation benefits are provided to employees.
Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange
for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the
amount of cash is determined by reference to the share price.
The cost of equity-settled transactions is measured at fair value on grant date. Fair value is independently determined
using either the Binomial or Black-Scholes option pricing model that takes into account the exercise price, the term
of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying
share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting
conditions that do not determine whether the consolidated entity receives the services that entitle the employees
Page | 35
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
to receive payment. No account is taken of any other vesting conditions.
The cost of equity-settled transactions is recognised as an expense with a corresponding increase in equity over the
vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award,
the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The
amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less
amounts already recognised in previous periods.
The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying
either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on
which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as
follows:
•
•
during the vesting period, the liability at each reporting date is the fair value of the award at that date
multiplied by the expired portion of the vesting period.
from the end of the vesting period until settlement of the award, the liability is the full fair value of the
liability at the reporting date.
All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash
paid to settle the liability.
Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market
conditions are considered to vest irrespective of whether or not that market condition has been met, provided all
other conditions are satisfied.
If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been
made. An additional expense is recognised, over the remaining vesting period, for any modification that increases
the total fair value of the share-based compensation benefit as at the date of modification.
If the non-vesting condition is within the control of the consolidated entity or employee, the failure to satisfy the
condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee
and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining
vesting period, unless the award is forfeited.
If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining
expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled
and new award is treated as if they were a modification.
(p)
Fair value measurement
When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes,
the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date; and assumes that the transaction will take place
either: in the principal market; or in the absence of a principal market, in the most advantageous market.
Fair value is measured using the assumptions that market participants would use when pricing the asset or liability,
assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on
its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data
are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the
use of unobservable inputs.
Page | 36
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
(q)
Issued capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options
are shown in equity as a deduction, net of tax, from the proceeds.
(r)
Business combinations
The acquisition method of accounting is used to account for business combinations regardless of whether equity
instruments or other assets are acquired.
The consideration transferred is the sum of the acquisition-date fair values of the assets transferred, equity
instruments issued or liabilities incurred by the acquirer to former owners of the acquiree and the amount of any
non-controlling interest in the acquiree. For each business combination, the non-controlling interest in the acquiree
is measured at either fair value or at the proportionate share of the acquiree's identifiable net assets. All acquisition
costs are expensed as incurred to profit or loss.
On the acquisition of a business, the consolidated entity assesses the financial assets acquired and liabilities assumed
for appropriate classification and designation in accordance with the contractual terms, economic conditions, the
consolidated entity's operating or accounting policies and other pertinent conditions in existence at the acquisition-
date.
Where the business combination is achieved in stages, the consolidated entity remeasures its previously held equity
interest in the acquiree at the acquisition-date fair value and the difference between the fair value and the previous
carrying amount is recognised in profit or loss.
Contingent consideration to be transferred by the acquirer is recognised at the acquisition-date fair value.
Subsequent changes in the fair value of the contingent consideration classified as an asset or liability is recognised
in profit or loss. Contingent consideration classified as equity is not remeasured and its subsequent settlement is
accounted for within equity.
The difference between the acquisition-date fair value of assets acquired, liabilities assumed and any non-controlling
interest in the acquiree and the fair value of the consideration transferred and the fair value of any pre-existing
investment in the acquiree is recognised as goodwill. If the consideration transferred and the pre-existing fair value
is less than the fair value of the identifiable net assets acquired, being a bargain purchase to the acquirer, the
difference is recognised as a gain directly in profit or loss by the acquirer on the acquisition-date, but only after a
reassessment of the identification and measurement of the net assets acquired, the non-controlling interest in the
acquiree, if any, the consideration transferred and the acquirer's previously held equity interest in the acquirer.
Business combinations are initially accounted for on a provisional basis. The acquirer retrospectively adjusts the
provisional amounts recognised and also recognises additional assets or liabilities during the measurement period,
based on new information obtained about the facts and circumstances that existed at the acquisition-date. The
measurement period ends on either the earlier of (i) 12 months from the date of the acquisition or (ii) when the
acquirer receives all the information possible to determine fair value.
(s)
Earnings per share
Basic earnings per share
Basic earnings per share is calculated by dividing the profit attributable to the owners of MedAdvisor Limited,
excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary
shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the
financial year.
Page | 37
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Diluted earnings per share
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into
account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary
shares and the weighted average number of shares assumed to have been issued for no consideration in relation to
dilutive potential ordinary shares.
(t)
Financial instruments
Recognition
Financial instruments are initially measured at cost on trade date, which includes transaction costs, when the related
contractual rights or obligations exist. Subsequent to initial recognition these instruments are measured as set out
below.
Loans and receivables
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in
an active market and are stated at amortised cost using the effective interest rate method.
Financial liabilities
Non-derivative financial liabilities are recognised at amortised cost, comprising original debt less principal payments
and amortization.
(u)
Goods and services tax (GST)
Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not
recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or
as part of the expense.
Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST
recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement
of financial position.
Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing
activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.
Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax
authority.
(v)
Going concern
The financial statements have been prepared on the going concern basis, which contemplates continuity of normal
business activities and the realisation of assets and discharge of liabilities in the normal course of business.
As disclosed in the financial statements, the consolidated entity incurred a loss of $8,101,385 and had net cash
outflows from operating activities of $6,945,168 for the year ended 30 June 2019.
The Directors believe that it is reasonably foreseeable that the consolidated entity will continue as a going concern
and that it is appropriate to adopt the going concern basis in the preparation of the financial report after
consideration of the following factors: -
•
the Directors are assessing growth and investment options for MedAdvisor and future capital raisings may
be required to pursue these opportunities. MedAdvisor has a strong track record of raising capital and if
Page | 38
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
required the directors are confident of further successful capital raisings to support the business strategy
and operational requirements of the consolidated entity;
•
the Directors constantly review the capital requirements of the business in light of the operational and
growth plans for the business and will adjust those plans to reflect the capital that is available to execute
those plans.
(w) New or amended Accounting Standards and Interpretations adopted
The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by
the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. Any new
or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. The
following Accounting Standards and Interpretations are most relevant to the consolidated entity:
AASB 9 Financial Instruments
The consolidated entity has adopted AASB 9 from 1 July 2018. The standard introduced new classification and
measurement models for financial assets. A financial asset shall be measured at amortised cost if it is held within a
business model whose objective is to hold assets in order to collect contractual cash flows which arise on specified
dates and that are solely principal and interest. A debt investment shall be measured at fair value through other
comprehensive income if it is held within a business model whose objective is to both hold assets in order to collect
contractual cash flows which arise on specified dates that are solely principal and interest as well as selling the asset
on the basis of its fair value. All other financial assets are classified and measured at fair value through profit or loss
unless the entity makes an irrevocable election on initial recognition to present gains and losses on equity
instruments (that are not held-for-trading or contingent consideration recognised in a business combination) in other
comprehensive income ('OCI'). Despite these requirements, a financial asset may be irrevocably designated as
measured at fair value through profit or loss to reduce the effect of, or eliminate, an accounting mismatch. For
financial liabilities designated at fair value through profit or loss, the standard requires the portion of the change in
fair value that relates to the entity's own credit risk to be presented in OCI (unless it would create an accounting
mismatch). New simpler hedge accounting requirements are intended to more closely align the accounting
treatment with the risk management activities of the entity. New impairment requirements use an 'expected credit
loss' ('ECL') model to recognise an allowance. Impairment is measured using a 12-month ECL method unless the
credit risk on a financial instrument has increased significantly since initial recognition in which case the lifetime ECL
method is adopted. For receivables, a simplified approach to measuring expected credit losses using a lifetime
expected loss allowance is available.
AASB 15 Revenue from Contracts with Customers
The consolidated entity has adopted AASB 15 from 1 July 2018. The standard provides a single comprehensive model
for revenue recognition. The core principle of the standard is that an entity shall recognise revenue to depict the
transfer of promised goods or services to customers at an amount that reflects the consideration to which the entity
expects to be entitled in exchange for those goods or services. The standard introduced a new contract-based
revenue recognition model with a measurement approach that is based on an allocation of the transaction price.
This is described further in the accounting policies below. Credit risk is presented separately as an expense rather
than adjusted against revenue. Contracts with customers are presented in an entity's statement of financial position
as a contract liability, a contract asset, or a receivable, depending on the relationship between the entity's
performance and the customer's payment. Customer acquisition costs and costs to fulfil a contract can, subject to
certain criteria, be capitalised as an asset and amortised over the contract period.
The impact on the financial performance and position of the consolidated entity from the adoption of these
Accounting Standards has been assessed and no restatement of comparative disclosures is required.
Page | 39
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
(x)
New standards and interpretations issued but not yet effective
At the date of this financial report the following standards and interpretations, which may impact the entity in the
period of initial application, have been issued but are not yet effective.
(y)
Comparative figures
Where required by Accounting standards, comparative figures have been adjusted to conform to changes in
presentation for the current financial year.
Note 2: Critical accounting judgements, estimates and assumptions
The preparation of the financial statements requires management to make judgements, estimates and assumptions
that affect the reported amounts in the financial statements. Management continually evaluates its judgements and
estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its
judgements, estimates and assumptions on historical experience and on other various factors, including expectations
Page | 40
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
of future events, management believes to be reasonable under the circumstances. The resulting accounting
judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions
that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to
the respective notes) within the next financial year are discussed below.
Goodwill and other indefinite life intangible assets
The consolidated entity tests annually, or more frequently if events or changes in circumstances indicate impairment,
whether goodwill and other indefinite life intangible assets have suffered any impairment, in accordance with the
accounting policy stated in note 1. The recoverable amounts of cash-generating units have been determined based
on value-in-use calculations. These calculations require the use of assumptions, including estimated discount rates
based on the current cost of capital and growth rates of the estimated future cash flows.
The recoverable amount of the consolidated entity's goodwill has been determined by a value-in-use calculation
using a discounted cash flow model, based on a 3 year projection period approved by management and extrapolated
for a further 2 years using a steady rate, together with a terminal value.
Key assumptions are those to which the recoverable amount of an asset or cash-generating units is most sensitive.
The following key assumptions were used in the discounted cash flow model for the business:
(a) 21.16% (2018: 19.78%) pre-tax discount rate;
(b) 15-20% (2018: 5.0%) per annum projected revenue growth rate;
(c) 15-20% (2018: 5.0%) per annum increase in operating costs and overheads.
The discount rate of 21.16% pre-tax reflects management’s estimate of the time value of money and the consolidated
entity’s weighted average cost of capital, the risk-free rate and the volatility of the share price relative to market
movements.
Management believes the projected revenue and cost growth rate of 20% in years one and two, and 15% in years
three through to five, is prudent and justified based on current and expected growth in the business.
Based on the above an impairment charge has not been applied as the carrying amount of goodwill does not exceed
its recoverable amount for the business.
Sensitivity
The directors have made judgements and estimates in respect of impairment testing of goodwill. Should these
judgements and estimates not occur the resulting goodwill carrying amount may decrease. The sensitivities are as
follows:
(a) Revenue would need to decrease by more than 8.5% for the business before goodwill would need to be impaired,
with all other assumptions remaining constant.
(b) The discount rate would be required to increase by 30.56% on a pre-tax basis before goodwill would need to be
impaired, with all other assumptions remaining constant.
Management believes that other reasonable changes in the key assumptions on which the recoverable amount of
the goodwill is based would not cause the cash-generating unit’s carrying amount to exceed its recoverable amount.
If there are any negative changes in the key assumptions on which the recoverable amount of goodwill is based, this
would result in a further impairment charge for the goodwill.
Share-based payment transactions
The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair
Page | 41
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
value of the equity instruments at the date at which they are granted. The fair value is determined by using either
the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were
granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no
impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit
or loss and equity.
Impairment of non-financial assets other than goodwill and other indefinite life intangible assets
The consolidated entity assesses impairment of non-financial assets other than goodwill and other indefinite life
intangible assets at each reporting date by evaluating conditions specific to the consolidated entity and to the
particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is
determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number
of key estimates and assumptions.
Recovery of deferred tax assets
Deferred tax assets are recognised for deductible temporary differences only if the consolidated entity considers it
is probable that future taxable amounts will be available to utilise those temporary differences and losses.
Note 3: Earnings per share
Both the basic and diluted loss per share have been calculated using the loss attributable to shareholders of
MedAdvisor Limited as the numerator, i.e. no adjustments to profits were necessary during the year ended 30 June
2019.
Page | 42
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 4: Issued Capital
a. Fully paid ordinary shares
Movements in ordinary share capital
b.
Performance shares
Page | 43
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 4: Issued Capital – continued
1 Founder performance shares converted to ordinary shares in October 2017 upon the satisfaction of both of the following
milestones:
50% of the founder performance shares shall convert upon the “MedAdvisor Platform” being activated at 2,500 pharmacies
within a period of 2 years from the issue of the founder performance shares; and
50% of the founder performance shares shall convert upon the Company receiving annualised revenue from the MedAdvisor
business (calculated over two consecutive calendar quarters) of no less than $5,000,000, within a period of 3 years from the
issue of the founder performance shares.
2 Peloton Capital Pty Ltd performance converted to ordinary shares upon in October 2017 upon the satisfaction of both of
the following milestones:
50% of the Peloton performance shares shall convert upon the “MedAdvisor Platform” being activated at 2,500 pharmacies
within a period of 2 years from the issue of the Peloton performance shares; and
50% of the Peloton performance shares shall convert upon the Company receiving annualised revenue from the MedAdvisor
business (calculated over two consecutive calendar quarters) of no less than $5,000,000, within a period of 3 years from the
issue of the Peloton performance shares.
Macmillan Gold Pty Ltd (MMG) performance shares lapsed in November 2018, MMG did not achieve the performance
milestones within 3 years of their issue as required.
c.
Read rights
1 million of Mr Read’s Employment Rights are due to vest on 30 June 2020 on the condition that Mr Read is employed
by the Company at the vesting date.
d.
Options over unissued shares
Page | 44
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 4: Issued Capital – continued
d. Options over unissued shares - continued
1 Lead manager (Peloton) unlisted options are exercisable at $0.03 with an expiry date of 17 December 2018
2 Read unquoted employment rights are exercisable at no cost and have vested and are exercisable immediately
3 Bennetto unlisted options exercisable at $.0.03 with an expiry date of 12 November 2018
Employee Incentive Options
Employee incentive plan options are unquoted and will vest in accordance with the rules of the plan. Cancellation of
unvested employee incentive options occurs on termination of employment.
Page | 45
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 4: Issued Capital - continued
e.
Capital management
Management’s objective is to maintain optimal returns to shareholders and benefits for other stakeholders.
Management also aims to maintain a capital structure that ensures the lowest cost of capital available to the entity.
Management adjusts the capital structure to the extent possible to take advantage of favourable costs of capital or
high returns on assets. As the market is constantly changing, management may change the amount of dividends to
be paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.
The Company is not subject to any externally imposed capital requirements, nor does it focus on obtaining debt as a
key capital management tool.
Note 5: Reserves
Share options reserve
Page | 46
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 5: Reserves - continued
Foreign currency translation reserve
Note 6: Controlled entity
Name of controlled entity:
Health Enterprises 2 Pty Ltd (ACN: 141 345 904)
Date on which controlled gained
31 October 2016
Additional information
The comparative figures in this financial report include the activities of Health
Enterprises 2 Pty Ltd since the date of the acquisition, 1 November 2016.
Name of controlled entity:
MedAdvisor Welam UK Ltd.
Date on which controlled gained
5 April 2018
Additional information
The entity was formed to conduct operations in the United Kingdom. From the
date of incorporation to the end of the financial year the entity did not enter
into any financial transactions.
Name of controlled entity:
MedAdvisor Welam USA Inc.
Date on which controlled gained
9 April 2018
Additional information
The entity was formed to conduct operations in the United States of America.
The figures for year ended 30 June 2019 include the activities of MedAdvisor
Welam USA Inc. From the date of incorporation to the end of the previous
financial year the entity did not enter into any financial transactions.
Name of controlled entity:
ZP MedAdvisor Pte. Ltd.
Date on which controlled gained
21 February 2019
Additional information
The entity was formed to conduct operations in the Asian Region. From the date
of incorporation to the end of the financial year the entity did not enter into any
financial transactions.
Note 7: Operating segments
The Board has determined that the Company presently has two reporting segments. The first being the business
activities of the MedAdvisor medication management and adherence platform (MedAdvisor Platform) and the
second being the corporate function associated with being an ASX listed company. The Board monitors the Company
based on actual versus budgeted revenue and expenditure incurred. This internal reporting framework is the most
relevant to assist the Board with making decisions regarding the Company and its ongoing activities.
Page | 47
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 7: Operating segments – continued
Note 8: Revenues
Page | 48
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 8: Revenues - continued
Note 9: Expenses
Page | 49
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 9: Expenses – continued
Note 10: Income tax expense
Page | 50
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 10: Income tax expense - continued
Note 11: Auditors remuneration
Note 12: Cash and cash equivalents
Note 13: Trade and other receivables
Page | 51
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 13: Trade and other receivables - continued
Movements in the allowance for expected credit losses are as follows:
Note 14: Other assets
Page | 52
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 15: Property, plant and equipment
Page | 53
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note16: Intangible assets
Note 17: Trade and other payables
Page | 54
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 18: Income in advance
Note 19: Employee benefits
Note 20: Accumulated losses
Note 21: Financial risk management
The company’s financial instruments consist mainly of deposits with banks,
trade receivable and trade payables.
The totals for each category of financial instruments, measured in
accordance with AASB 9 as detailed in the accounting policies to these
financial statements, are as follows:
Page | 55
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 21: Financial risk management – continued
Financial Risk Management Policies
The Directors' overall risk management strategy seeks to assist the company in meeting its financial targets,
whilst minimising potential adverse effects on financial performance. Risk management policies are approved
and reviewed by the Directors' on a regular basis. These include credit risk policies and future cash flow
requirements.
Specific Financial Risk Exposures and Management
The main risks the Entity is exposed to through its financial instruments are interest rate risk, liquidity risk, credit
risk and foreign currency risk.
Interest Rate Risk
a.
Exposure to interest risk arises on financial assets and financial liabilities recognised at reporting date whereby a
future change in interest rates will affect future cash flows or the fair value of fixed rate financial instruments
b. Liquidity Risk
Liquidity risk arises from the possibility that the company might encounter difficulty in settling its debts or
otherwise meeting its obligations related to financial liabilities. The Entity manages this risk through the following
mechanisms:
Preparing forward looking cash flow analysis in relation to its operational, investing and financing activities.
Credit Risk
c.
Exposure to credit risk relating to financial assets arises from the potential non−performance by counter parties of
contract obligations that could lead to a financial loss to the Entity.
Credit risk is managed through the maintenance of procedures (such procedures include the utilisation of systems
for the approval, granting and removal of credit limits, regular monitoring of exposures against such limits and
monitoring of the financial stability of significant customers and counter parties), ensuring to the extent possible,
that customers and counter parties to transactions are of sound credit worthiness. Such monitoring is used in
assessing receivables for impairment. Credit terms are generally 30 days from the invoice date. Customers who
do not meet the Entity's strict credit policies may only purchase in cash or only use recognised credit cards.
Page | 56
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 21: Financial risk management – continued
Credit Risk Exposures
The maximum exposure to credit risk by class of recognised financial assets at balance date is equivalent to the
carrying value and classification of those financial assets (net of any allowance for expected credit loss) as
presented in the balance sheet.
Trade and other receivables that are neither past due or impaired are considered to be of high credit quality.
Aggregates of such amounts are as detailed in Note 13.
Foreign currency risk
d.
The consolidated entity undertakes certain transactions denominated in foreign currency and is exposed to foreign
currency risk through foreign exchange rate fluctuations.
Foreign exchange risk arises from future commercial transactions and recognised financial assets and financial
liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using
sensitivity analysis and cash flow forecasting. The consolidated entity the foreign exchange risk to be low and has
not entered into any forward foreign exchange contracts.
The carrying amount of the consolidated entity's foreign currency denominated financial assets and financial
liabilities at the reporting date were as follows:
The consolidated entity had net assets denominated in foreign currencies of $121,439 (assets of $154,263 less
liabilities of $32,824) as at 30 June 2019 (2018: Nil)). Based on this exposure, had the Australian dollar weakened by
5% (2018: not applicable) against these foreign currencies with all other variables held constant, the consolidated
entity's loss before tax for the year would have been $7,007 lower (2018: not applicable) and equity would have
been $7,007 lower (2018: not applicable). The percentage change is the expected overall volatility of the significant
currencies, which is based on management’s assessment of reasonable possible fluctuations taking into
consideration movements over the last 6 months each year and the spot rate at each reporting date. The actual
foreign exchange gain for the year ended 30 June 2019 was $33,063 (2018: Nil).
Fair value estimation
The fair values of financial assets and financial liabilities are presented in the following table and can be compared
to their carrying values as presented in the balance sheet. Fair values are those amounts at which an asset could be
exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction.
Fair values derived may be based on information that is estimated or subject to judgment, where changes in
assumptions may have a material impact on the amounts estimated. Areas of judgment and the assumptions have
been detailed below. Where possible, valuation information used to calculate fair value is extracted from the
market, with more reliable information available from markets that are actively traded. In this regard, fair values
for listed securities are obtained from quoted market bid prices. Where securities are unlisted, and no market quotes
are available, fair value is obtained using discounted cash flow analysis and other valuation techniques commonly
used by market participants.
Page | 57
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 21: Financial risk management – continued
Differences between fair values and carrying amounts on financial instruments with fixed interest rates are due to
the change in discount rates being applied by the market since their initial recognition by the company. Most of the
instruments which are carried at amortised cost are to be held until maturity and therefore the net fair value figures
calculated bear little relevance to the company.
Page | 58
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 22: Reconciliation of profit/(loss) after tax to net cash flow from operations
Note 23: Contingencies
There were no contingent liabilities or contingent assets at the date of this report to affect the financial statements.
Note 24: Capital and leasing commitments
On 21 July 2015 the Company entered into a non-cancellable operating lease for new offices. On the 26 April 2018
the Company assigned this operating lease to an unrelated third party. The assignment of the lease transferred all of
the Company’s obligation under the operating lease to the third party while at the same time transferring the rights
of ownership of the leasehold improvements made by the Company. The effect of this transaction was that the
Company has brought to account a loss of $115,607 from the write-off of the leasehold improvements.
On 28 December 2017 the Company entered into a non-cancellable operating lease for replacement offices
commencing on 1 January 2018 for a term of 7 years. The lease has provided for an initial rent-free period of 12
months together with a cash contribution from the landlord of $68,900 to over make good costs from the previous
tenant.
Page | 59
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 24: Capital and leasing commitments - continued
Note 25: Events subsequent to the reporting date
There have been no matters or circumstances which have arisen since the end of the financial period that significantly
affected, or may significantly affect the operations of the Entity, the results of those operations or the state of affairs
of the Entity, in future years.
Note 26: Other related party transactions
Other related parties include close family members of key management personnel and entities that are controlled
or jointly controlled by those key management personnel individually or collectively with their close family members.
Transactions between related parties are on normal commercial terms and conditions no more favourable than those
available to other persons unless otherwise stated.
NostraData Pty Ltd is an associated entity of the Company which has entered into the following related party
transaction with the Company during the financial year.
SwinTech Pty Ltd is an associated entity of the Company which has entered into the following related party
transaction with the Company during the financial year.
Page | 60
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 26: Other related party transactions – continued
Note 27: Parent entity information
Set out below is the supplementary information about the parent entity.
Contingent liabilities
The parent entity had no contingent liabilities as at 30 June 2019 and 30 June 2018.
Capital commitments – property plant & equipment
The parent entity had no capital commitments for property plant & equipment as at
30 June 2019 and 30 June 2018.
Significant accounting policies
The accounting policies of the parent entity are consistent with those of the
consolidated entity as disclosed in Note 1.
Page | 61
MEDADVISOR LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR YEAR ENDED 30 JUNE 2019
Note 28: Key management personnel disclosures
Compensation
The aggregate compensation made to directors and other members of
key management personnel of the consolidated entity is set out below:
Page | 62
MEDADVISOR LIMITED
DIRECTORS’ DECLARATION
The Directors of the Company declare that:
1.
The consolidated financial statements and notes, as set out on pages 25 to 62, are in accordance with the
Corporations Act 2001 and:
(a)
(b)
comply with Accounting Standards which as stated in accounting policy Note 1 to the financial
statements, constitutes explicit and unreserved compliance with International Financial Reporting
Standards (IFRS); and
give a true and fair view of the financial position as at 30 June 2019 and of the performance for the
year ended on that date of the Company;
2.
the Director’s have declared that:
(a)
(b)
(c)
the financial records of the Company for the financial year have been properly maintained in
accordance with section 286 of the Corporations Act 2001;
the financial statements and notes for the financial year comply with the Accounting Standards; and
the financial statements and notes for the financial year give a true and fair view; and
3.
in the Directors’ opinion, there are reasonable grounds to believe that the Company will be able to pay its
debts as and when they become due and payable.
This declaration is made in accordance with a resolution of the Board of Directors.
Peter Bennetto
Chairman
29 August 2019
Camberwell, VIC.
Page | 63
INDEPENDENT AUDITOR’S REPORT
To the Members of MedAdvisor Limited
Opinion
We have audited the financial report of MedAdvisor Limited (the Company) and its subsidiaries (the Group), which
comprises the consolidated statement of financial position as at 30 June 2019, the consolidated statement of profit
or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated
statement of cash flows for the year then ended, and notes to the financial statements, including a summary of
significant accounting policies, and the directors' declaration.
In our opinion the accompanying financial report of the Group is in accordance with the Corporations Act 2001,
including:
I.
giving a true and fair view of the Group's financial position as at 30 June 2019 and of its financial
performance for the year then ended; and
II.
complying with Australian Accounting Standards and the Corporations Regulations 2001.
Basis for Opinion
We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those
standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of
our report. We are independent of the Group in accordance with the auditor independence requirements of the
Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board's
APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial
report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.
We confirm that the independence declaration required by the Corporations Act 2001, which has been given to
the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's
report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our
opinion.
Key Audit Matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of
the financial report of the current period. These matters were addressed in the context of our audit of the financial
report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.
Page | 64
Key Audit Matters (Continued.)
Key Audit Matter
How our audit addressed this matter
Recognition of Revenue
Refer to Note 8 in the financial statements
Revenue recognition was considered a key audit
matter. MedAdvisor receives revenue from two core
income streams, and the accounting for each of
these differs.
While subscription revenues are not complex and do
not involve significant management judgements, the
recognition of revenue generated from Patient
Education Programs (“PEP”) involves management
estimates around the timing of delivery of services.
Our audit procedures in relation to the recognition of
revenue included:
• Assessing whether
revenue
recognition policies were in compliance with AASB
15 Revenue from Contracts with Customers;
the Group’s
• Evaluating
the operating effectiveness of
revenue
related
to
management’s controls
recognition;
• Performing
substantive
analytical
review
procedures on subscription revenues;
• Performing detailed testing on a sample of PEP
revenues recognised and assessing the allocation
of revenue to various elements in the contracts
with customers; and
• Reviewing sales transactions before and after
year-end to ensure that revenue is recognised in
the correct period.
Impairment of Goodwill
Refer to Note 16 in the financial statements
The consolidated entity has goodwill of $4,013,868
as at 30 June 2019.
Our audit procedures in relation to management’s
impairment assessment included:
We identified this area as a key audit matter due to
the size of the goodwill balance and because the
directors’ assessment of the ‘value in use’ of the
cash generating unit
this
Goodwill involves judgements about the future
underlying cash flows of the business and the
discount rate applied to them.
(“CGU”) containing
Management performed an impairment assessment
over the balance of intangible assets by calculating
the value in use for the individual CGU identified
using a discounted cash flow model and comparing
the resulting value in use of the CGU to its carrying
value.
Management also performed a sensitivity analysis
over the value in use calculations by varying the
assumptions used (growth rates, terminal growth
rate and WACC) to assess the impact on the
valuations.
• Assessing management’s determination that the
Goodwill should be allocated to a single CGU
based on the nature of the Group’s business and
the manner in which results are monitored and
reported;
• Assessing the overall valuation methodology used
to determine the value in use;
• Challenging
the
reasonableness
key
assumptions, including the cash flow projections,
revenue growth
rates, and
sensitivities used;
rates, discount
of
• Checking the mathematical accuracy of the cash
flow model, and
to
supporting evidence such as approved budgets,
and considering the reasonableness of these
budgets; and
input data
reconciling
• Reviewing the accuracy of disclosures of critical
financial
valuation
estimates and assumptions
statements
to
in
methodologies.
relation
the
the
in
Page | 65
Other Information
The directors are responsible for the other information. The other information comprises the information included
in the Group's annual report for the year ended 30 June 2019 but does not include the financial report and the
auditor's report thereon.
Our opinion on the financial report does not cover the other information and accordingly we do not express any
form of assurance conclusion thereon.
In connection with our audit of the financial report, our responsibility is to read the other information and, in doing
so, consider whether the other information is materially inconsistent with the financial report or our knowledge
obtained in the audit or otherwise appears to be materially misstated.
If, based on the work we have performed, we conclude that there is a material misstatement of this other
information, we are required to report that fact. We have nothing to report in this regard.
Responsibilities of the Directors for the Financial Report
The directors of the Company are responsible for the preparation of the financial report that gives a true and fair
view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal
control as the directors determine is necessary to enable the preparation of the financial report that gives a true
and fair view and is free from material misstatement, whether due to fraud or error.
In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as
a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of
accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic
alternative but to do so.
Auditor's Responsibilities for the Audit of the Financial Report
Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from
material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance
with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements
can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably
be expected to influence the economic decisions of users taken on the basis of this financial report.
A further description of our responsibilities for the audit of the financial report is located at the Auditing and
Assurance Standards Board website at: http://www.auasb.gov.au/auditors_responsibilities/ar2.pdf.
This description forms part of our auditor's report.
Page | 66
Report on the Remuneration Report
Opinion on the Remuneration Report
We have audited the Remuneration Report included in the directors' report for the year ended 30 June 2019.
In our opinion, the Remuneration Report of MedAdvisor Limited, for the year ended 30 June 2019, complies with
section 300A of the Corporations Act 2001.
Responsibilities
The directors of the Company are responsible for the preparation and presentation of the Remuneration Report
in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the
Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.
RSM AUSTRALIA PARTNERS
P A RANSOM
Partner
Dated: 29 August 2019
Melbourne, Victoria
Page | 67
MEDADVISOR LIMITED
SHAREHOLDER INFORMATION
30 JUNE 2019
The shareholder information set out below was applicable as at 26 August 2019.
Distribution of equitable securities
Analysis of number of equitable security holders by size of holding:
Equity security holders
Twenty largest quoted security holders
The names of the twenty largest security holders of quoted equity securities are listed below:
Page | 68
MEDADVISOR LIMITED
SHAREHOLDER INFORMATION
30 JUNE 2019 - continued
The names of the twenty largest security holders of quoted equity securities are listed below: - continued
Unquoted equity securities
Options over ordinary shares issued
Substantial shareholders
Substantial shareholders in the company are set out below:
Page | 69